Clinical Trial Update: A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating a VRD-based regimen in combination with CART-ASCT-CART2 therapy for primary plasma cell leukemia and is currently recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plasma Cell Leukemia

Drugs mentioned

• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Plasma Cell Leukemia | Phase 2 | Status: RECRUITING